IP Verse

Methods Of Administering Fluvoxamine Therapy - EP2653162

The patent EP2653162 was granted to Intermune on May 20, 2020. The application was originally filed on Dec 3, 2010 under application number EP13176914A. The patent is currently recorded with a legal status of "Revoked".

EP2653162

INTERMUNE
Application Number
EP13176914A
Filing Date
Dec 3, 2010
Status
Revoked
Jun 16, 2023
Grant Date
May 20, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALFRED E TIEFENBACHERFeb 19, 2021HAMM & WITTKOPPWITHDRAWN
INTAS PHARMACEUTICALSFeb 19, 2021ACCORD HEALTHCAREWITHDRAWN
AERAFeb 16, 2021AERAWITHDRAWN
SANDOZFeb 10, 2021ELKINGTON AND FIFEWITHDRAWN

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP2324831
OTHEREP2324831

Non-Patent Literature (NPL) Citations (23) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BAUCR ET AL., AAPS JOURNAL, (2007), vol. 9, no. 1, pages E60 - 83-
DESCRIPTION- BROSEN ET AL., "Fluvoxamine is a potent inhibitor of cytochrome P4501A2", BIOCHEM PHARMACOL, (1993), vol. 45, pages 1211 - 1214-
DESCRIPTION- BROSEN, "The pharmacogenetics of the selective serotonin reuptake inhibitors", CLIN INVEST, (1993), vol. 71, no. 12, pages 1002 - 1009-
DESCRIPTION- HEMERYCK ET AL., "Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update", CURRENT DRUG METABOLISM, (2002), vol. 3, no. 1, pages 13 - 37-
DESCRIPTION- JEPPESEN ET AL., "Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine", EUR J CLIN PHARMACOL, (1996), vol. 51, pages 73 - 78-
DESCRIPTION- LEAPE LL ET AL., JAMA, (1995), vol. 274, no. 1, pages 35 - 43-
DESCRIPTION- MCCLELLAN ET AL., "Fluvoxamine An Updated Review of its Use in the Management of Adults with Anxiety Disorders", ADIS DRUG EVALUATION, (200010), vol. 60, no. 4, pages 925 - 954-
DESCRIPTION- RASCHETTI R ET AL., BUR J CLIN PHARMACOL, (1999), vol. 54, no. 12, pages 959 - 963-
DESCRIPTION- RASMUSSEN, "Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine", BR J CLIN PHARMACOL, (1995), vol. 39, pages 151 - 159-
OPPOSITION- FDA, "Guidance for Industry, Drug Interaction Studies - Study Design, Data Analysis, and Implications for dosing and Labeling", (20060900), XP055783976-
OPPOSITION- FDA, "Guidance for Industry, Drug Interaction Studies - Study Design, Data Analysis, and Implications for dosing and Labeling", Draft Guidance, (20060900), XP055783976-
OPPOSITION- FDA, "Luvox® (fluvoxamine maleate) Tablets for oral administration", Highlights of Prescribing Information, (20080000), pages 1 - 31, XP055786467-
OPPOSITION- MICHALETS, "Update: Clinically Significant Cytochrome P-450 Drug Interactions", Pharmacotherapy, (19980000), vol. 18, no. 1, pages 84 - 112, XP055106914-
OPPOSITION- BROSEN et al., "Fluvoxamine is a Potent Inhibitor of Cytochrome P 4501A2", Biochemical Pharmacology, (19930000), vol. 45, no. 6, doi:10.1016/0006-2952(93)90272-X, pages 1211 - 1214, XP025541928
OPPOSITION- HEMERYCK et al., "Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update", Current Drug Metabolism, (20020000), vol. 3, doi:10.2174/1389200023338017, pages 13 - 37, XP009157243
OTHER- FDA et al, "Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling", Guidance for Industry, (20060900), pages 1 - 51-
SEARCH- Banu A. Karimi-Shah, MD, "Clinical Review, NDA 22-535", (20100212), URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203081.pdf, (20100429), XP002580220 [XP] 1-12 * Division Summary, paragraph linking pages 4-5 * * Clinical Briefing Document, page 17, Section 4.4.2; page 17 * * Clinical Briefing Document, page 87, Section 7.5.3 *-
SEARCH- Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare, "Report on the Deliberation Results", (20080916), URL: http://www.pmda.go.jp/english/service/pdf/Pirespa-Pirfenidone.pdf, (20100422), XP009132612 [AD] 1-12 * pages 25-26: section 3.(ii).A.(3).5 * * page 27: section 3.(ii).A.(5) * * pages 43-44: section 4.(i).B * * page 63 - page 64 *-
SEARCH- "Intermune, Inc; Pirfenidone Briefing Document", (20100309), URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM203083.pdf, (20100429), XP002580221 [XP] 1-12 * Sections: "Elimination" and "3.2 Drug-Drug Interactions"; page 37 *-
SEARCH- JEPPESEN U ET AL, "Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER VERLAG, DE, (19960101), vol. 51, no. 1, ISSN 0031-6970, pages 73 - 78, XP009132566 [AD] 1-12 * the whole document *-
SEARCH- KROON LISA A, "Drug interactions with smoking", AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS, UNITED STATES, (20070915), vol. 64, no. 18, ISSN 1079-2082, pages 1917 - 1921, XP009151842 [A] 1-12 * the whole document *-
SEARCH- LANDI M T ET AL, "Human cytochrome P4501A2.", IARC SCIENTIFIC PUBLICATIONS 1999 LNKD- PUBMED:10493258, (1999), no. 148, ISSN 0300-5038, pages 173 - 195, XP009132024 [A] 1-12 * abstract * * page 176, column left, paragraph L * * Page 185: "Clinical implications" *-
SEARCH- HEMERYCK ALEX ET AL, "Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: An update", CURRENT DRUG METABOLISM, (200202), vol. 3, no. 1, ISSN 1389-2002, pages 13 - 37, XP009157243 [AD] 1-12 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents